Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/ml100051d http://scihub22266oqcxt.onion/10.1021/ml100051d C4007794!4007794!24900195     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       ACS+Med+Chem+Lett 2010 ; 1 (5): 204-8 Nephropedia Template TP {{tp|p=24900195|t=2010. Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases |pdf=|usr=}}{{24900195}} gab.com Text Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases JO: ACS Med Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=24900195 #FOAvip Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation. Twit Text FOAVip Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases ????ACS Med Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=24900195 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24900195 #FOAvip English Wikipedia <ref>{{Cite pmid|24900195}}</ref> Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases #MMPMID24900195 Paruch K; Dwyer MP; Alvarez C; Brown C; Chan TY; Doll RJ; Keertikar K; Knutson C; McKittrick B; Rivera J; Rossman R; Tucker G; Fischmann T; Hruza A; Madison V; Nomeir AA; Wang Y; Kirschmeier P; Lees E; Parry D; Sgambellone N; Seghezzi W; Schultz L; Shanahan F; Wiswell D; Xu X; Zhou Q; James RA; Paradkar VM; Park H; Rokosz LR; Stauffer TM; Guzi TJ ACS Med Chem Lett 2010[Aug]; 1 (5): 204-8 PMID24900195show ga Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation. äDiscovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor(epmc).pdf DeepDyve Pubget Overpricing